Current questions in HIV-associated lung cancer

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 511-517

  Shcherba, Marina ^a   Shuter, Jonathan ^b   Haigentz Jr , Missak ^a,b  

^a Department of Medicine   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; HIV; Lung cancer; Smoking cessation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CARBOPLATIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; PEMETREXED; PROTEINASE INHIBITOR; TAXANE DERIVATIVE; VINCA ALKALOID;

AGE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DAMAGE; DNA REPAIR; EARLY CANCER; EARLY DIAGNOSIS; ESOPHAGITIS; GENE MUTATION; GENE REARRANGEMENT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; LUNG CARCINOGENESIS; ODYNOPHAGIA; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SMOKING; COMPLICATION; HUMAN; LUNG NEOPLASMS; ONSET AGE; RISK FACTOR;

AGE OF ONSET; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; LUNG NEOPLASMS; RISK FACTORS; SMOKING;

EID: 84883242187     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328363dfdb     Document Type: Review

References (55)

1. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117: 1089-1096.
2. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
3. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103: 753-762.
4. Pantanowitz L, Dezube BJ. Evolving spectrum and incidence of non-AIDSdefining malignancies. Curr Opin HIV AIDS 2009; 4: 27-34.
5. Flanders WD, Lally CA, Zhu BP, et al. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res 2003; 63: 6556-6562.
6. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol 2004; 21: 109-115.
7. Ruiz M. Lung cancer in HIV-infected patients: the experience of an urban clinic. J Int Assoc Physicians AIDS Care (Chic Ill) 2010; 9: 214-217.
8. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43: 47-55.
9. Giordano TP, Kramer Jr. Does HIV infection independently increase the incidence of lung cancer? Clin Infect Dis 2005; 40: 490-491.
10. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153: 452-460.
11. Burkhalter JE, Springer CM, Chhabra R, et al. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res 2005; 7: 511-522.
12. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged 18 years-United States, 2009. Morb Mortal Wkly Rep 2010; 59: 1135-1140.
13. Mani D, Haigentz M Jr, Aboulafia DM. Lung cancer in HIV Infection. Clin Lung Cancer 2012; 13: 6-13. A comprehensive review article on risk factors, screening, treatment, and outcomes in HIV-associated lung cancer.
14. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012; 26: 1017-1025. This article presents data from the VACS-VC that showed that HIV infection appears a risk factor for lung cancer even when controlling for many other variables.
15. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45: 103-110.
16. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV infected individuals. J Clin Oncol 2006; 24: 1383-1388.
17. Jung G, Chung J, Shuter J, et al. Lung cancer in HIV infection: a case series. J Clin Oncol 2008; 26:; suppl; abstr 19093.
18. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21: 207-213.
19. Pacht ER, Diaz P, Clanton T, et al. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest 1997; 112: 785-788.
20. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumonia and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005; 14: 773-778.
21. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
22. Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-622.
23. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
24. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011; 103: 1112-1122.
25. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2551-2559.
26. Prosperi MCF, Cozzi-Lepri A, Castagna A, et al. Icona Foundation Study Group. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 1316-1321.
27. Guiguet M, Boue F, Cadranel J, et al. Clinical Epidemiology Group of the FHDHANRSCO4 Cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152-1159.
28. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306-5315.
29. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52: 1458-1465.
30. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
31. Carter MM, Torres SM, Cook DL Jr, et al. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen 2007; 48: 239-247.
32. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
33. Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80: 42-49.
34. Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012; 26: 2223-2231.
35. Nunnari G, Smith JA, Daniel R. HIV-1 Tat and AIDS-associated cancer: targeting the cellular anticancer barrier? J Expr Clin Cancer Res 2008; 27: 3.
36. McLemore MS, Haigentz M Jr, Smith RV, et al. Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol 2010; 4: 97-105.
37. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
38. Vadakara J, Borghaei H. Personalized medicine and treatment approaches in nonsmall-cell lung carcinoma. Pharmgenomics Pers Med 2012; 5: 113-123.
39. Lavole A, Wislez M, Antoine M, et al. Lung cancer, a new challenge in the HIVinfected population. Lung Cancer 2005; 51: 1-11.
40. Silverberg M, Chao C, Leyden W, et al. Cancer stage, age at diagnosis, and survival comparing HIV+ and HIV-individuals with common non-AIDS-defining cancers; CROI Meeting, Abstract #903; 2012.
41. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virusassociated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118: 164-172. This retrospective review of 80 patients with HIV-associated lung cancer at a single institution emphasized an observation that higher CD4+ cell count was associated with improved outcomes.
42. Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas. AIDS 2013; 27: 459-468. This cancer and HIV-linked, registry-based study highlights differences in treatment and outcomes in HIV-infected patients and reports less favorable outcomes and lack of appropriate and aggressive treatment in this population.
43. Rengan R, Mitra N, Liao K, et al. Effect of HIV on survival in patients with nonsmall-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012; 13: 1203-1209. This SEER-based study did not identify significant differences in clinical outcomes between patients with HIV and uninfected patients with NSCLC.
44. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008; 26: 1027-1032.
45. Weiss SA, Gajavelli S, Negassa A, et al. Evaluation of cancer trial eligibility criteria (with focus on non-AIDS-defining cancers) for inclusion of persons with HIV infection. J Clin Oncol 2011; 29:; suppl; abstr 6092.
46. Tirelli U, Spina M, Sandri S, et al. The Italian Cooperative Group on AIDS and Tumors. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer 2000; 88: 563-569.
47. Leigh BR, Lau DH. Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Am J Clin Oncol 1998; 21: 479-481.
48. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in cancer patients with HIV/AIDS. Lancet Oncol 2011; 12: 905-912.
49. Srirangam A, Milani M, Mitra R, et al. The HIV protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol 2011; 6: 661-670.
50. Rengan R, Mick R, Pryma D, et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012; 7: 709-715.
51. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52: 203-208.
52. National Comprehensive Cancer Network. Lung cancer screening. 2013; http://www.nccn.com/files/cancer-guidelines/lung-screening/index.html [Accessed on 8 April 2013]
53. American Cancer Society. Nonsmall cell lung cancer detection. 2013; http://www.cancer.org/cancer/lungcancer-nonsmallcell/detailedguide/ nonsmallcell-lung-cancer-detection [Accessed on 8 April 2013]
54. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
55. Sigel M, Brown S, Wisnivesky J, et al. Chest CT scan findings and implications for lung cancer screening in asymptomatic HIV infected patients; CROI Meeting Abstract #907; 2012.